| To: patriots70 who wrote (12819) | 9/15/2020 4:40:16 PM | | From: iamajesuit | | | | Excellent article! Just discovered following on Seeking Alpha
Healthcare
Scientists isolate tiny antibody that neutralizes SARS-CoV-2
Sep. 15, 2020 4:19 PM ET|About: Eli Lilly and Company (LLY)|By: Douglas W. House, SA News Editor
Scientists at the University of Pittsburgh School of Medicine (UPMC) have isolated an antibody, dubbed Ab8, that is 10x smaller than a full-sized antibody used in drugs and completely neutralizes the SARS-CoV-2 virus.
The data, published in the journal Cell, showed that Ab8 was highly effective in preventing and treating COVID-19 in mice and hamsters.
The scientists says Ab8's small size increases its potential for diffusion in tissues, increasing efficacy, while being potentially suitable for alternative routes of administration such as inhalation. A bonus is that it does not bind to human cells, thereby avoiding unwanted side effects.
Ab8 was identified by "fishing" in a pool of more than 100B potential candidates using the SARS-CoV-2 spike protein as bait. It is created when the VH domain is fused to part of the immunoglobulin tail region, adding the immune functions of a full-sized antibody without the bulk.
Abound Bio, a newly formed UPMC-backed company, has in-licensed the rights to Ab8 for global development.
Selected tickers: Eli Lilly (NYSE: LLY), Gilead Sciences (NASDAQ: GILD), Vir Biotechnology (NASDAQ: VIR), Regeneron Pharmaceuticals (NASDAQ: REGN) |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Savant | 9/16/2020 7:26:53 AM | | | | | | planning....possibly...
NanoViricides (NYSEMKT: NNVC) perks up 7% premarket on light volume in reaction to its announcement that it has selected a drug candidate, dubbed NV-CoV-1-R, for the treatment of COVID-19.
The company says NV-CoV-1-R consists of a nanoviricide, NV-CoV-1 with Gilead Sciences' (NASDAQ: GILD) remdesivir encapsulated inside its core, adding that NV-CoV-1 is designed to attack the virus particles themselves and "possibly" would also attack infected cells that express a coronavirus antigen called S-protein. Normal cells, which would not display the S-protein, would be unaffected. The encapsulation of remdesivir, it claims, may protect it from rapid metabolism, increasing its stability and effectiveness.
Clinical trials are planned.
Shares are down 34% over the past six months. |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: old 'n cranky who wrote (12815) | 9/16/2020 3:59:04 PM | | From: HardToFind | | | | They're fishing for a lead plaintiff and taking longer to catch one than it should take. If only they would open up their lawsuit to corporate behavior over the last 15 years instead of just 9 months, I could be quite helpful. (Hell...I think I have an audio of their lawyer lying to me during an annual shareholder meeting Q&A, certainly making a blatantly deceptive statement.)
But I used the last speculative Covid-19 bounce to sell out at $12, so I can't really claim I have been harmed by their recent drug campaign...although whoever I sold my shares to was certainly adversely affected. (Sorry about that...) |
| | NNVC - NanoViricides, Inc. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| |
